Although PARP inhibitors and cisplatin are classified together in the current study, the frequently observed differences in patient sensitivities to these drugs, suggest that there are different thresholds for the gene panel and the HR status in cancer patients (if quantified by i.e., COSMIC signature 3, ShallowHRD or HRD score, etc.). Here, PARP1 is linked to cancer.